- 2 immunoassay targeting imported diseases common in migrant populations
- 3 **Running title:** Multi-infection screening by Luminex technology
- 4 Authors

- 5 Ruth Aguilar<sup>#1</sup>, PhD; Angeline Cruz<sup>#1</sup>, MSc; Alfons Jiménez<sup>1,2</sup>, PhD; Alex Almuedo<sup>1</sup>, MSc;
- 6 Carme Roca Saumell<sup>3,4</sup>, PhD; Marina Gigante Lopez<sup>5</sup>, MD; Oriol Gasch<sup>6</sup>, PhD; Gemma
- 7 Falcó<sup>7</sup>, MD; Ana Jiménez-Lozano<sup>8</sup>, PhD; Angela Martínez-Perez<sup>9</sup>, PhD; Consol Sanchez-
- 8 Collado<sup>10</sup>, MD; Andrea Tedesco<sup>11</sup>, MD; Manuel Carlos López<sup>12</sup>, PhD; María Jesús Pinazo<sup>1,13</sup>,
- 9 PhD; Thais Leonel<sup>14</sup>, MSc; Zeno Bisoffi<sup>11</sup>, PhD, Prof; Anna Färnert<sup>15,16</sup>, PhD, Prof; Carlota
- 10 Dobaño†<sup>1,13</sup>, PhD Prof; Ana Requena-Méndez†<sup>1,13,15,16</sup>, MD, PhD.
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de
   Barcelona. Carrer Roselló 132, 08036 Barcelona, Spain.
- Biomedical *Research* Networking Center for *Epidemiology and Public Health* (CIBERESP). Avenida Monforte de Lemos 3-5, 28029 Madrid, Spain.
- Centre d'Atenció Primaria El Clot, Institut Català de la Salut (ICS). Carrer
   Concilio de Trento 25, 08018 Barcelona, Spain.
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB). Carrer
   Casanova, 143, 08036 Barcelona, Spain
- Centre d'Atenció Primaria Center Numància, Institut Català de la Salut (ICS).
   Carrer Numància 23, 08029 Barcelona, Spain.
- Infectious Diseases Department, Hospital Universitari Parc Taulí. Institut
   d'Investigació i Innovació Parc Taulí. Universitat Autònoma de Barcelona. Parc
   Taulí, 1, 08208 Sabadell-Barcelona, Spain.
- Centre d'Atenció Primaria Sant Miquel, Institut Català de la Salut (ICS). Carrer
   Francesc Macià i Llussà, 154, 08401 Granollers-Barcelona, Spain.
- Centre d'Atenció Primaria Adrià 5A Marc Aureli, Institut Català de la Salut (ICS).
   Carrer Vallmajor, 34, 08021 Barcelona, Spain.
- Centre d'Atenció Primaria Casanova. Consorci d'Atenció Primària de Salut de
   l'Eixample (CAPSBE) Casanova. Carrer Rosselló 161, 08036 Barcelona, Spain.
- 31 10. Centre d'Atenció Primaria Torelló, Institut Català de la Salut (ICS). Avenida
- Pompeu Fabra, 8, 08570 Torelló-Barcelona, Spain.

  NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 11. Department of Infectious Tropical diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital. Via Sempreboni 5, 37024 Negrar di Valpolicella, Italy.
  - 12. Spanish National Research Council (IPBLN-CSIC). Avenida del Conocimiento 17, Parque Tecnológico de Ciencias de la Salud, 18016, Granada, Spain.
  - Biomedical *Research* Networking Center (CIBER) of Infectious Diseases, Carlos
     III Health Institute (CIBERINFEC, ISCIII). Carrer Melchor Fernández Almagro,
     3, 28029 Madrid, Spain.
- 14. Liver Unit, Hospital Clínic, University of Barcelona, August Pi i Sunyer
   Biomedical Research Institute (IDIBAPS), Biomedical Research Networking
   Center of Hepatic and Digestive Diseases (CIBEREHD). Carrer Villarroel, 170,
   08036 Barcelona, Spain.
  - 15. Department of Medicine Solna, Karolinska Institutet. Solnavägen 1, 17177 Solna-Stockholm, Sweden.
- 16. Department of Infectious Diseases, Karolinska University Hospital. Solnavägen 1,
   17177 Solna-Stockholm, Sweden.
- 50 \*Both authors contributed equally.
- †Both authors contributed equally.
- Grants that funded the project:
- This study was supported by two grants from Instituto de Salud Carlos III (ISCIII), through
- the "Fondo de Investigación para la Salud (FIS)", PI17/02020 and PI20/00866.
- 56 ARM receives funding from the Strategic Research Program in Epidemiology at Karolinska
- 57 Institutet.

34

35

36

37

38

39

40

45

46

49

- 58 The research team was supported by CIBER-Consorcio Centro de Investigación Biomédica
- 59 en Red-(CB 2021).
- 60 MCL was supported by the Programa Estatal I+D+I, Spanish Ministry of Science and
- 61 Innovation and FEDER (PID2019-109090RB-I00/AEI/10.13039/501100011033).
- 62 Authors from IRCCS Sacro Cuore Don Calabria Hospital were supported by the Italian
- 63 Ministry of Health "Fondi Ricerca corrente-L2P4".

Part of the data from this study were presented in the European Conference of Clinical Microbiology and Infectious Diseases in Copenhagen (April 2023). **Corresponding author** Ana Requena-Méndez Karolinska Institutet, Department of Medicine Solna. Barcelona Institute for Global Health requena.mendez@ki.se Tel: +46702010789 

**Abstract** 

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

**Background:** In this study we have evaluated the performance of a novel multiplex serological assay with a panel of 8 antigens able to simultaneously detect IgG to HIV, chronic hepatitis B (HBV) and C (HCV), Chagas disease, strongyloidiasis and schistosomiasis as a screening tool for imported diseases in migrants. Methods: Six panels of 40 well-characterized, anonymized serum samples from individuals with the respective confirmed infections (n=240) were used as positive controls to assess the sensitivity of the multiplex assay. One panel of 40 sera from non-infected subjects were used to estimate the seropositivity cutoffs for each infection, and 32 additional non-infected sera were used as negative controls to estimate the sensitivity and specificity for each serology. The multi-infection screening test was validated in a prospective cohort of 48 migrants from endemic areas to assess assay performance. The sensitivity of the Luminex assay was calculated as the proportion of positive test results over all positive samples by the primary reference test. The specificity was calculated using 32 negative samples. Uncertainty was quantified with 95% confidence intervals (CI) using receiver operating characteristic analyses. **Results:** The sensitivity /specificity were 100%/100% for HIV (p41 antigen), 97.5%/100% (AUC:0.99,[95%CI: 0.96-1.00]) for HBV (core antigen), 100%/100% (AUC:1.00,[95%CI 1.00-1.00]) for HCV (core antigen), 92.5%/90.6%,(AUC:0.96,[95%CI 0.91-1.00]) for strongyloidiasis (31-kDa recombinant antigen (NIE)), 97.5%/100%,(AUC:0.97,[95%CI 0.93-1]) for schistosomiasis (combined serpin *Schistosoma mansoni* and *S.haematobium* antigens) and 92.5%/96.9%,(AUC: 0.96,[95%CI 0.92-1.00]) for Chagas disease ([*T.cruzi* kinetoplastid membrane protein-11 (KMP11)]). In the migrant cohort, antibody response to KMP11 correctly identified 14/14(100%) individuals with Chagas disease, whereas HBV-core antigen and NIE-Strongyloides correctly identified 91.7% and 86.4% individuals with chronic hepatitis B and strongyloidiasis

Conclusions: We have developed a new 8-plex Luminex assay that is robust and accurate, 109 and could facilitate the implementation of screening programmes for imported diseases in 110

migrant populations. 111

respectively.

113 Key words: Migrants, Hepatitis C virus, Hepatitis B virus, Strongyloides, Schistosomiasis,

Chagas disease, Luminex, IgG, sensitivity, specificity, screening, imported diseases, travel-

related illnesses.

114

### INTRODUCTION

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

Migration is a complex and growing global phenomenon, of critical importance to European, North American and other countries such as Australia and New Zealand (Western countries). Most migrants are disproportionately affected by certain infections such as tuberculosis, human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), and multiple studies have reported higher prevalence of such infections among them compared with autochthonous populations. 1,2 In 2020, 44% of new HIV diagnoses were attributed to migrants living in the European Union, particularly migrants from sub-Saharan Africa.3 Similarly, migrants from certain regions are at increased risk of hepatitis B and C whereas for other regions, the risk is even lower compared to the autochthonous population.<sup>2</sup> Other parasitic infections, such as Chagas disease, strongyloidiasis and schistosomiasis, which are not endemic in Western countries, -with the exception of strongyloidiasis in few areas-, are highly prevalent among migrants 4-6. Chagas disease, caused by *Trypanosoma cruzi* is a public health concern due to the high pooled prevalence (4.2%) among migrants from Latin-American endemic countries living in Europe<sup>5</sup>, which is particularly high in Bolivian migrants (18%)<sup>7</sup>; but also due to the possibility of autochthonous transmission (congenitally, by transfusion, or transplantation, 8) with a subsequent increase of related morbidity in national health systems from Western countries, particularly in immunosuppressed patients due to the risk of reactivation. Strongyloidiasis is also an emerging infection which is of public health concern due to the possibility of being a life-threatening pathology when immunosuppression is established. 10 Schistosomiasis is a neglected tropical disease becoming relevant in low- and non-endemic countries because of the increased migration flows from high-endemic countries. It represents a management challenge due to the lack of clinical awareness and knowledge among health professionals.<sup>11</sup> Early detection and treatment of these infections can lower the related morbidity and mortality. 11 The European Centre for Disease Prevention and Control (ECDC) guidance on screening of infections in migrants, 12 recommends the screening of HIV, HBV, HCV, strongyloidiasis and schistosomiasis. Chagas disease was not included in the ECDC screening and vaccination recommendations document, yet this disease has an impact in Europe's health system and some studies have demonstrated the cost-effectiveness of the strategy of screening migrants from endemic countries at primary care.<sup>8</sup>

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

7

The feasibility of innovative integrated screening programmes of infectious diseases, has been proven in different settings including primary care units in United Kingdom, United States, Canada and Spain. 11,13-15 Antibody-based assays are used for assessing the exposure to different infections among migrants including HIV or viral hepatitis, <sup>16</sup> and also parasites (Strongyloides stercoralis<sup>17</sup>, Schistosoma spp<sup>18</sup> and T. cruzi<sup>19</sup>) for which methods aiming at the direct detection of the parasites or their DNA have lower sensitivity. Quantitative suspension array assays simultaneously detecting antibodies to multiple pathogens using a single specimen can support a more cost-effective implementation of integrated disease surveillance systems. In addition, rapid tests with single but also with multiple biomarkers are gaining popularity in low-income countries. In this regard, the dual rapid HIV and Treponema pallidum diagnostic test is an example of multiple-test that has been utilized in integrated screening systems. Luminex technology is gaining traction in diagnosis because of the ease, high throughput, and minimal sample volume requirements. It has been used to perform the surveillance of tropical viral infections,<sup>20</sup> enteropathogens,<sup>21</sup> or malaria.<sup>22</sup> More recently another new multiplex-test has been developed to detect HIV, viral hepatitis, herpes and T. pallidum.<sup>23</sup> Our study aimed to develop a new multiplex serological assay using 10 antigens to quantify IgG to six pathogens that are prevalent in migrant populations living in Catalonia (Spain), including HIV, HBV, HCV, T. cruzi, S. stercoralis and Schistosoma spp., and to estimate its sensitivity and specificity compared with primary reference standard tests for each infection. **METHODS** Study design The study was performed using six panels of archived, fully anonymized well-characterized coded serum samples previously diagnosed for the different infections, plus a group of samples from non-infected subjects. Each panel consisted of 40 positive control specimens for each pathogen (HIV, HBV, HCV, T. cruzi, Strongyloides and Schistosoma). HIV positive controls were determined with the Determine HIV-1/2 Rapid Test (Abbott Laboratories) and confirmed with the Unigold rapid test (Trinity Biotech). HBV and HCV positive controls were determined by RNA quantitative testing that measures the viral load. The schistosomiasis positive controls were positive for

## Multi-infection IgG Luminex assay.

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

The 10 antigens initially selected for the study are listed in Table 1. P24 (core antigen) and gp41 (envelope antigen) were selected for HIV serology, the first one for being indicative of acute infection<sup>27</sup> and the second one for being highly immunogenic during seroconversion<sup>28</sup>

epimastigotes antigen<sup>26</sup>, with diagnosis defined by positivity in both serological tests.

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

9

the 31-kDa recombinant antigen (NIE) antigen was selected for the serology of S. stercoralis, as ELISAs based on this antigen have shown high sensitivity in the range of 71– 84% 25,29,30 S.mansoni (Sm) and S.haematobium (Sh) serpins were selected for the serology of the corresponding species for being reported as promising species-specific diagnostic antigens by Luminex<sup>31</sup>, hepatitis C core and nonstructural protein 3 (NS3) antigens were tested for chronic hepatitis C infection, the core antigen is currently used for diagnostic<sup>32</sup> and the NS3 antigen has also been reported as seroreactive<sup>33</sup>, hepatitis B core (anti-HBc) antigen was used for the detection of chronic hepatitis B infection as the presence of IgG indicates ongoing infection, and people who have immunity to hepatitis B from a vaccine do not develop anti-HBc<sup>34</sup>. Finally, paraflagellar rod proteins 2 (PFR2)1 and *T.cruzi* kinetoplastid membrane protein-11 (KMP11) antigens were selected for being previously reported as good markers of *T.cruzi* infection<sup>35</sup>. Each of the 10 antigens included in the Luminex panel was coupled to a specific magnetic microsphere region; the optimal bead-coupling concentration was determined for each using the same methodology, as described previously.<sup>36</sup> A detailed description of the assays is provided in Annex 2. Briefly, 361 samples were tested together with serial dilutions of a positive control to generate a standard curve for assay quality control, plus 3 technical blanks. Antigen-coupled microspheres were added in multiplex to the 384-well plate (2000 beads/ antigen/ well) and mixed with test samples, positive controls, and blanks. Final dilution of test samples was 1/250. The plate was incubated for 1 h at room temperature in agitation and protected from light. Then, the plate was washed and 25µL of goat anti-human IgG-phycoerythrin,(1:400) were added to each well and incubated for 30 min. The plate was washed again and microspheres resuspended with Luminex Buffer, to be acquired on the Flexmap-3D® reader. At least 50 microspheres/analyte/well were acquired, and median fluorescence intensity (MFI) was reported. Annex 3 shows the standard curves made of 20 serial dilutions of the positive control. Reference standard results were blinded to the researchers who performed the Luminex test. **Data analysis** 

MFI cutoffs for seropositivity were calculated for each antigen as the exponential function of

the mean plus 2 standard deviations (SD) or 3SD of log<sub>10</sub>-transformed MFIs of 40 negative

controls randomly selected among the specimens from 72 subjects with no previous exposure

to any infection. The other 32 negative controls were used to estimate the specificity of the Luminex assay vs the reference tests. Thereafter, for each infection, the evaluation of the Luminex assay performance used 72 specimens with known serological status (40 positive and 32 negative samples). The sensitivity of the Luminex test was calculated as the proportion of positive results (based on the cut-off with 2SD) over all positive samples by the primary reference test. Sensitivity was also calculated with the cutoff with 3SD. Similarly, specificity was calculated over 32 control negative samples from the group of healthy controls using both 2SD and 3SD cutoffs. Uncertainty was quantified with 95% confidence intervals (CI) using receiver operating characteristic (ROC) analyses. Finally, the sensitivity and specificity were also estimated in a panel of samples prospectively collected from 48 migrants at risk of infections.

### **Ethics**

244

245

246

247

248

249

250

251

252

253

254

255

262

263

264

- Positive and negative control samples used to develop the assay were obtained from collections registered at the Instituto de Salud Carlos III, Hospital Clínic(Barcelona)/ISGlobal biobanks and Sacro-Cuore Hospital Tropica-Biobank (Annex 4). The study protocol and informed consent from migrants whose samples were prospectively collected were approved by the ethical committee at Hospital Clínic, (HCB/2017/0847). Results are reported
- according to the STARD-checklist (Annex 5).

### RESULTS

### Accuracy of the multi-infection Luminex assay on a reference panel of human samples

- We evaluated the performance of the novel multiplex serological assay on a panel of human
- sera with known infection status. First, we estimated the seropositivity cutoffs for each of the
- antigens in the Luminex panel using 2 and 3SD, summarized in Annex 6.
- Figure 1 represents the IgG serological levels (log<sub>10</sub>MFI) against each antigen in the Luminex
- panel in 32 negative and 246 positive control samples (1A), and 48 test samples from
- 270 migrants exposed to the infections (1B).
- Using a 2SD cutoff, the sensitivity was generally high (>90%) for the majority of the
- antigens, whereas the specificity depended on the pathogen and antigen (Table 2 and Figure
- 273 2). The sensitivity and specificity of the Luminex test for detecting HIV using the gp41
- 274 recombinant protein determined by ROC analysis were 100% using both 2SD and 3SD

- cutoffs. In contrast, the p24 protein performed worse, with a sensitivity of 87.5% and a
- specificity of 96.9% with the 2SD cutoff, and 80% sensitivity at 3SD cutoff (Figure 2A).
- The HBV core antigen showed a sensitivity of 97.5% at 2SD-cutoff and 95% at 3SD-cutoff,
- and a specificity of 100% (2SD and 3SD-cutoff), (AUC: 0.99, [95%CI: 0.96-1.00]), (Figure
- 279 2B). The HCV core antigen showed a 100% sensitivity at 2SD-cutoff (97.5% at 3SD-cutoff)
- and a specificity of 100% (2SD and 3SD-cutoff), (AUC: 1.00, [95% CI 1.00-1.00]), (Figure
- 281 2C).
- 282 Strongyloides-NIE antigen reported a sensitivity of 92.5% (2SD and 3SD-cutoff) and
- 283 specificities of 90.6% (2SD-cutoff) and 100% (3SD-cutoffs), (AUC:0.96, [95%CI 0.91-
- 1.00]), (Figure 2D). In a restricted analysis (Annex 7) to those samples that tested positive in
- feces [(either by polymerase chain reaction (PCR) test or any other direct technique]), the
- performance of the NIE antigen in Luminex with the 3SD cutoff improved to 100%
- 287 sensitivity (AUC: 1.00, [95%CI 1.00-1.00]).
- 288 The sensitivity and specificity of the Luminex test to detect schistosomiasis was 97.5% and
- 289 93.8% (2SD cutoff),(AUC:0.97, [95%CI 0.93-1.00]) using S. haematobium (Sh) and S.
- 290 mansoni (Sm) serpin antigens together, (Figure 2E). Interestingly, the sensitivity of the
- serpin-Sh antigen was 100% for detecting S. haematobium infections whereas the sensitivity
- of the serpin-Sm antigen was 96% for detecting *S. mansoni* infections (Annex 7).
- The T. cruzi KMP11 antigen performed better (Sen 92.5%, Spec 96.9%, AUC:0.96, [95%CI
- 294 0.92-1.00]) compared to the PFR2 antigen (Sen 77.5%; Spec 93.8, AUC:0.87, [95% CI 0.80-
- 295 0.94]). Furthermore, when combining both antigens, the sensitivity increased to 95%
- 296 (AUC:0.97, [95%CI 0.93-1.00]) (Figure 2F). There were two samples in the *T. cruzi* infection
- 297 panel that resulted indeterminate by the reference test, and it was necessary a third serological
- test to confirm the infection. After excluding these samples from the analysis (Annex 7), the
- sensitivity increased to 97.4% at 2SD cutoff (AUC:0.98, [95%CI 09.95-1.00]).
- 300 In order to assess possible cross-reactivities, we evaluated for each infection the false positive
- rate among the individuals from the six panels of positive controls (Annex 8). Overall, the
- Luminex serology showed a low frequency of false positives, except for S. stercoralis
- showing a rate of 66% (12/18) and 50% (9/18) among *Schistosoma* spp. Infections at a cutoff
- of 2SD and 3SD respectively, and 62% (13/21) and 38% (8/21) in Schistosoma spp. and HBV
- coinfections at a cutoff of 2SD and 3SD respectively. There were 25% (5/20) false positives

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

12

(97.5%) and the combination of *T. cruzi* antigens (95%).

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

expensive.

15

based settings where the detection of single pathogens can be logistically challenging and

### Acknowledgements

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

We are grateful to all patients who participated in this study, the general practitioners, nurses, and other staff from the primary care centres and hospitals who were committed to perform the field work required for the study while maintaining their daily tasks. Specially, we acknowledge the work carried by Maria Luisa Machado and Silvia Capilla from Hospital Universitari Parc Taulí. Special thanks to the research group at the IRCCS Sacro Cuore Don Calabria Hospital for providing the positive control samples for strongyloidiasis (part of them) and schistosomiasis, in particular to Stefano Tais and Monica Degani, to Jose Munoz (Hospital Clinic, Barcelona) for facilitating positive control samples for strongyloidiasis (part of them) and Denise Naniche (ISGlobal) for information on the HIV positive control samples. We are also grateful to Ma Carmen Thomas from the Institute of Parasitology and Biomedicine López Neyra for supplying the Chagas disease antigens, Thomas Nutman (NIH/NIAID,USA), Sukwan Handali (CDC) for supplying the NIE, Satoshi Kaneko (Nagasaki University, Japan) for donating the Sm and Sh serpins, and Marta Vidal, Rebeca Santano and Inocencia Cuamba for support in the antigen procurement and characterization.

## **Funding**

This study was supported by two grants from Instituto de Salud Carlos III (ISCIII), cofinanced by the European Regional Development Fund (FEDER) from the European Union, through the "Fondo de Investigación para la Salud (FIS)", PI17/02020 and PI20/00866. ARM receives funding from the Strategic Research Program in Epidemiology at Karolinska Institutet. This research team was supported by CIBER-Consorcio Centro de Investigación Biomédica en Red-(CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea. MCL was supported by the Programa Estatal I+D+I, Spanish FEDER Ministry of Science and Innovation and (PID2019-109090RB-I00/AEI/10.13039/501100011033). Authors from IRCCS Sacro Cuore Don Calabria Hospital were supported by the Italian Ministry of Health "Fondi Ricerca corrente-L2P4". ISGlobal receives support from the Spanish Ministry of Science and Innovation through the "Centro de Excelencia Severo Ochoa 2019-2023" Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.

The funders of the study had no role in the study design, data collection, data analysis, data interpretation or writing of the manuscript.

Author contribution

Study design by ARM, RA, AJ and CD. Field work done by CRS, MGL, OGB, GF, AJL, AMP, RSC. Sample processing carried out by AJ, RA and CD. Methodology developed by RA, AC and ARM. Interpretation of results executed by AC, ARM and AJ. The manuscript has been drafted by RA, AC, AJ, CD and ARM. All authors have contributed to the writing, reviewing and editing of the publication.

### REFERENCES

- 477 1 European Centre for Disease Prevention and Control. Assessing the burden of key
- 478 infectious diseases affecting migrant populations in the EU/EEA. Stockholm, 2014
- 479 DOI:10.2900/28792.
- 480 2 Lazarus J V., Bromberg DJ, del Amo J, et al. Hepatitis C prevalence among the
- 481 migrant population in Spain: A systematic review and meta-analysis. Enferm Infecc
- 482 Microbiol Clin 2019; 37: 222–30.
- 483 3 European Centre for Disease Prevention and Control, WHO Regional Office for
- Europe. HIV/AIDS surveillance in Europe 2021 2020 data. Stockholm: ECDC, 2021.
- 485 4 Asundi A, Beliavsky A, Liu XJ, et al. Prevalence of strongyloidiasis and
- 486 schistosomiasis among migrants: a systematic review and meta-analysis. Lancet Glob Health
- 487 2019; 7: e236–48.
- 488 5 Requena-Méndez A, Aldasoro E, de Lazzari E, et al. Prevalence of Chagas disease in
- 489 Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS
- 490 Negl Trop Dis 2015; 9: e0003540.
- 491 6 Navarro M, Reguero L, Subir C, Bl A, Requena-m A. Estimating chagas disease
- 492 prevalence and number of underdiagnosed, and undertreated individuals in Spain. 2022 May-
- 493 June; 47:102284. DOI:10.1016/j.tmaid.2022.102284.
- 494 7 1 European Centre for Disease Prevention and Control. Assessing the burden of
- key infectious diseases affecting migrant populations in the EU/EEA. Stockholm, 2014
- 496 DOI:10.2900/28792.
- 497 2 Lazarus J V., Bromberg DJ, del Amo J, et al. Hepatitis C prevalence among the
- 498 migrant population in Spain: A systematic review and meta-analysis. Enferm Infecc Microbiol
- 499 Clin 2019; 37: 222–30.
- 500 3 European Centre for Disease Prevention and Control, WHO Regional Office for
- 501 Europe. HIV/AIDS surveillance in Europe 2021 2020 data. Stockholm: ECDC, 2021.
- 502 4 Asundi A, Beliavsky A, Liu XJ, et al. Prevalence of strongyloidiasis and
- schistosomiasis among migrants: a systematic review and meta-analysis. Lancet Glob Health
- 504 2019; 7: e236–48.
- 505 5 Requena-Méndez A, Aldasoro E, de Lazzari E, et al. Prevalence of Chagas disease in
- Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS
- 507 Negl Trop Dis 2015; 9: e0003540.
- Navarro M, Reguero L, Subir C, Bl A, Requena-m A. Estimating chagas disease
- prevalence and number of underdiagnosed, and undertreated individuals in Spain. 2022; 47.
- 510 DOI:10.1016/j.tmaid.2022.102284.
- Requena-Mendez A, Buonfrate D, Bisoffi Z, Gutiérrez JM. Advances in the
- 512 Diagnosis of Human Strongyloidiasis. Curr Trop Med Rep 2014; 1: 207–15.

- 8 Requena-Méndez A, Bussion S, Aldasoro E, et al. Cost-effectiveness of Chagas
- disease screening in Latin American migrants at primary health-care centres in Europe: a
- Markov model analysis. Lancet Glob Health 2017; 5: e439–47.
- Requena-Méndez A, Albajar-Viñas P, Angheben A, Chiodini P, Gascón J, Muñoz J.
- 517 Health Policies to Control Chagas Disease Transmission in European Countries. PLoS Negl
- Trop Dis 2014 Oct 30; 8(10):e3245. DOI:10.1371/journal.pntd.0003245.
- 519 10 Buonfrate D, Requena-Mendez A, Angheben A, et al. Severe strongyloidiasis: a
- 520 systematic review of case reports. BMC Infect Dis 2013 Feb 8; 13: 78.
- 521 11 Sequeira-Aymar E, Cruz A, Serra-Burriel M, et al. Improving the detection of
- 522 infectious diseases in at-risk migrants with an innovative integrated multi-infection screening
- 523 digital decision support tool (IS-MiHealth) in primary care: A pilot cluster-randomized
- 524 controlled trial. J Travel Med 2022 Nov 4; 29(7):taab100.
- 525 12 ECDC. Public health guidance on screening and vaccination for infectious diseases in
- newly arrived migrants within the EU/EEA. 2018.
- 527 13 Eborall H, Wobi F, Ellis K, et al. Integrated screening of migrants for multiple
- 528 infectious diseases: Qualitative study of a city-wide programme. EClinicalMedicine 2020
- 529 Apr 18; 21:100315.
- María JM, Vivancos J, Lidia CG, et al. Hepatitis C and HIV combined screening in
- primary care: A cluster randomized trial. J Viral Hepat. 2021 Feb;28(2):345-352.
- Redditt VJ, Graziano D. Health status of newly arrived refugees in Toronto, Ont. Can
- 533 Fam Physician. 2015 Jul; 61(7): e303–e309
- 534 16 Zangiabadian M, Zamani A, Nasiri MJ, Behzadi E, Fooladi AAI. Diagnostic
- Accuracy and Validity of Serological and Molecular Tests for Hepatitis B and C. Curr Pharm
- 536 Biotechnol 2022; 23: 803–17.
- Requena-Mendez A, Chiodini P, Bisoffi Z, et al. The laboratory diagnosis and follow
- up of strongyloidiasis: a systematic review. PLoS Negl Trop Dis 2013; 7: e2002.
- 539 18 Agbata EN, Morton RL, Bisoffi Z, et al. Effectiveness of Screening and Treatment
- 540 Approaches for Schistosomiasis and Strongyloidiasis in Newly-Arrived Migrants from
- Endemic Countries in the EU/EEA: A Systematic Review. Int J Environ Res Public Health.
- 542 2018 Dec 20;16(1):11. DOI:10.3390/ijerph16010011.
- 543 19 Abras A, Gállego M, Llovet T, et al. Serological Diagnosis of Chronic Chagas
- Disease: Is It Time for a Change? J Clin Microbiol 2016; 54: 1566–72.
- Raulino R, Thaurignac G, Butel C, et al. Multiplex detection of antibodies to
- Chikungunya, O'nyong-nyong, Zika, Dengue, West Nile and Usutu viruses in diverse non-
- 547 human primate species from Cameroon and the Democratic Republic of Congo. PLoS Negl
- 548 Trop Dis 2021; 15: 1–20.
- 549 21 Williams C, Cumming O, Grignard L, et al. Prevalence and diversity of enteric
- pathogens among cholera treatment centre patients with acute diarrhea in Uvira, Democratic
- 551 Republic of Congo. BMC Infect Dis 2020 Oct;20(1):741. DOI:10.1186/S12879-020-05454-0.

- 552 22 Tetteh KKA, Wu L, Hall T, et al. Optimisation and standardisation of a multiplex
- 553 immunoassay of diverse Plasmodium falciparum antigens to assess changes in malaria
- 554 transmission using sero-epidemiology. Wellcome Open Res 2020 Apr 23;4:26.
- 555 DOI:10.12688/WELLCOMEOPENRES.14950.2.
- Yufenyuy EL, Vedapuri S, Zheng A, et al. Development of a Bead-Based Multiplex
- Assay for Use in Multianalyte Screening and Surveillance of HIV, Viral Hepatitis, Syphilis,
- and Herpes. J Clin Microbiol 2022 May 18;60(5):e0234821. DOI:10.1128/JCM.02348-21.
- 559 24 Buonfrate D, Salas-Coronas J, Muñoz J, et al. Multiple-dose versus single-dose
- ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-
- label, phase 3, randomised controlled superiority trial. Lancet Infect Dis 2019; 19: 1181–90.
- 562 25 Bisoffi Z, Buonfrate D, Sequi M, et al. Diagnostic Accuracy of Five Serologic Tests
- for Strongyloides stercoralis Infection. PLoS Negl Trop Dis 2014; 8: e2640.
- Riera C, Vergés M, López-Chejade P, et al. Desarrollo y evaluación de una técnica
- 565 ELISA con antígeno crudo de Trypanosoma cruzi para el diagnóstico de la Enfermedad de
- 566 Chagas. Enferm emerg 2009;11(1):22-29.
- 567 27 Saz J, Dalmau-Bueno A, Meulbroek M, et al. Use of fourth-generation rapid
- 568 combined antigen and antibody diagnostic tests for the detection of acute HIV infection in a
- community centre for men who have sex with men, between 2016 and 2019. PLoS One 2021
- 570 Jul 27;16(7):e0255065. DOI:10.1371/JOURNAL.PONE.0255065.
- 571 28 Mayer-Blackwell K, Johnson AM, Potchen N, et al. Multi-trial analysis of HIV-1
- 572 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines.
- 573 Front Immunol 2022 Oct 12;13:983313.
- 574 29 Krolewiecki AJ, Ramanathan R, Fink V, et al. Improved diagnosis of Strongyloides
- 575 stercoralis using recombinant antigen-based serologies in a community-wide study in
- 576 northern Argentina. Clinical and Vaccine Immunology 2010; 17: 1624–30.
- 577 30 Fradejas I, Herrero-Martínez JM, Lizasoaín M, Rodríguez De Las Parras E, Pérez-
- 578 Ayala A. Comparative study of two commercial tests for Strongyloides stercoralis serologic
- 579 diagnosis. Trans R Soc Trop Med Hyg 2018; 112: 561–7.
- Tanigawa C, Fujii Y, Miura M, et al. Species-Specific Serological Detection for
- Schistosomiasis by Serine Protease Inhibitor (SERPIN) in Multiplex Assay. PLoS Negl Trop
- 582 Dis 2015; 9: e0004021.
- 583 32 NICE: The National Institute for Health and Care excellence. Hepatitis B and C
- testing: people at risk of infection. 2012. URL: https://www.nice.org.uk/guidance/ph43.
- 585 (Accessed June 8, 2023).
- Marohnic CC, Birkenmeyer LG, Bogdan MF, et al. Engineering of the hepatitis C
- virus helicase for enhanced seroreactivity. J Virol Methods 2019; 264: 11–7.
- 588 34 Interpretation of Hepatitis B Serologic Test Results | CDC.
- https://www.cdc.gov/hepatitis/hbv/interpretationOfHepBSerologicResults.htm (accessed May
- 590 31, 2023).

- 591 35 Egui A, Carmen Thomas M, Fernández-Villegas A, et al. A Parasite Biomarker Set
- 592 for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic
- Trypanosoma cruzi Infection. Antimicrob Agents Chemother 2019 Sep 23;63(10):e02436-18.
- 594 DOI:10.1128/AAC.02436-18/SUPPL\_FILE/AAC.02436-18-S0001.PDF.
- 595 36 Ubillos I, Aguilar R, Sanz H, et al. Analysis of factors affecting the variability of a
- 596 quantitative suspension bead array assay measuring IgG to multiple Plasmodium antigens.
- 597 PLoS One 2018; 13: e0199278.
- 598 37 Viana IFT, Coêlho DF, Palma ML, et al. Detection of IgG3 antibodies specific to the
- 599 human immunodeficiency virus type 1 (HIV-1) p24 protein as marker for recently acquired
- 600 infection. Epidemiol Infect 2018; 146: 1293–300.
- Brust S, Duttmann H, Gürtler L, Thortensson R, Simon F. Shortening of the
- diagnostic window with a new combined HIV p24 antigen and anti-HIV-1/2/O screening test.
- 603 J Virol Methods 2000; 90: 153–65.
- Gauna A, Losada S, Lorenzo M, et al. Use of Synthetic Peptides and Multiple Antigen
- Blot Assay in the Immunodiagnosis of Hepatitis C Virus Infection. Viral Immunol 2018; 31:
- 606 568-74.
- 607 40 Gam AA, Neva FA, Krotoski WA. Comparative sensitivity and specificity of ELISA
- and IHA for serodiagnosis of strongyloidiasis with larval antigens. Am J Trop Med Hyg
- 609 1987; 37: 157–61.
- 610 41 Kelly EA, Bulman CA, Gunderson EL, et al. Comparative Performance of Latest-
- 611 Generation and FDA-Cleared Serology Tests for the Diagnosis of Chagas Disease. J Clin
- 612 Microbiol 2021 May 19;59(6):e00158-21. DOI:10.1128/JCM.00158-21.
- 613 42 Arnold B, Scobie H, Priest J, Lammie P. Integrated serologic surveillance of
- population immunity and disease transmission. Emerg Infect Dis 2018; 24: 1188–94.
- Priest J, Jenks M, Moss D, et al. Integration of multiplex bead assays for parasitic
- diseases into a national, population-based serosurvey of women 15-39 years of age in
- 617 Cambodia. PLoS Negl Trop Dis 2016 May 3;10(5):e000469.
- 618 44 Fujii Y, Kaneko S, Nzou S, et al. Serological surveillance development for tropical
- 619 infectious diseases using simultaneous microsphere-based multiplex assays and finite mixture
- 620 models. PLoS Negl Trop Dis 2014 Jul 31;8(7):e304.
- 621 45 McManus M, Karalius B, Patel K, Persaud D, Luzuriaga K. Quantitative HIV-1-
- 622 specific antibodies as predictors of peripheral blood cell-associated HIV-1 DNA
- 623 concentrations. AIDS 2020; 34: 1117–26.
- 624 46 Santano R, Rubio R, Grau-Pujol B, et al. Evaluation of antibody serology to
- determine current helminth and Plasmodium falciparum infections in a co-endemic area in
- Southern Mozambique. PLoS Negl Trop Dis 2022 Jun 21;16(6):e0010138.
- 627 47 Tanigawa C, Fujii Y, Miura M, et al. Species-Specific Serological Detection for
- 628 Schistosomiasis by Serine Protease Inhibitor (SERPIN) in Multiplex Assay. PLoS Negl Trop
- 629 Dis 2015 Aug 20;9(8):e000402.

## 649 **TABLES**

# Table 1. The 10 antigens tested used in the multi-infection Luminex assay

651

650

Antigen	Pathogen	Source	Coupling	Reference
Recombinant HIV1 p24 protein	HIV	Abcam ab43037	concentration 30μg/mL	37
Recombinant HIV1 gp41 protein	HIV	Abcam ab49068	250μg/mL	45
NIE	Strongyloides	Expressed in <i>E. coli</i> by Sukwan Handali (CDC) from a plasmid clone donated by Thomas Nutman (NIH/NIAID), USA	10μg/mL	46
Sm serpin	Schistosoma mansoni	Donated by Satoshi Kaneko (Nagasaki University, Japan)	30μg/mL	47
Sh serpin	Schistosoma haematobium	Donated by Satoshi Kaneko (Nagasaki University, Japan)	50μg/mL	47
Recombinant Hepatitis C Virus NS3 protein	HCV	Abcam ab49024	50μg/mL	48
Recombinant Hepatitis C Virus Core Antigen	HCV	Abcam ab49017	50μg/mL	48
Recombinant Hepatitis B Virus Core Antigen	HBV	Abcam ab49013	30μg/mL	49, 50
Chagas PFR2	Trypanosoma cruzi	Recombinant protein produced by Carmen Thomas and Manuel C. Lopez, IPBLN-CSIC, Granada, Spain	50μg/mL	51
Chagas KMP11	Trypanosoma cruzi	Recombinant protein produced by Carmen Thomas and Manuel C. Lopez IPBLN-CSIC, Granada, Spain)	30μg/mL	51
	1	1. 5.71		1

HIV: Human Immunodeficiency Virus, HBV: Hepatitis B Virus, HCV: Hepatitis C Virus; Sm: *Schistosoma mansoni*; Sh: *Schistosoma haematobium*; NS3: non-structural protein 3; PFR2: paraflagellar rod protein 2; KMP11: kinetoplastid membrane protein-11 652

Table 2. Performance parameters of the 10 antigens tested in the multiplex assay on a reference panel of human samples

		2 SD cutoff						AUC				
	Antigens	Pos T / Pos GS		Neg T / Neg GS	NOCOTTO IT	Correctly classified			Neg T / Neg GS	Specificity	Correctly classified	
HIV	p24	35/40	87.5	31/32	96.9	91.7	32/40	80.0	32/32	100	88.9	0.93 (0.88-0.99)
	gp41	40/40	100	32/32	100	100	40/40	100	32/32	100	100	1.00 (1.00-1.00)
	Both	40/40	100	31/32	96.9	98.6	40/40	100	32/32	100	100	1.00 (1.00-1.00)
HBV	HBV core	39/40	97.5	32/32	100	98.6	38/40	95	32/32	100	97.2	0.99 (0.96-1.00)
HCV HO	HCV core	40/40	100	32/32	100	100	39/40	97.5	32/32	100	98.6	1.00 (1.00-1.00)
	HCV NS3	33/40	82.5	31/32	96.9	88.9	31/40	77.5	32/32	100	87.5	0.91 (0.85-0.97)
	Both	40/40	100	31/32	96.9	98.6	39/40	97.5	32/32	100	98.6	1.00 (1.00-1.00)
Chagas disease	PFR2	31/40	77.5	30/32	93.8	84.7	17/40	42.5	32/32	100	68.1	0.87 (0.80-0.94)
	KMP11	37/40	92.5	31/32	96.9	94.4	34/40	85.0	32/32	100	91.7	0.96 (0.92-1.00)
	Both	38/40	95.0	29/32	90.6	93.1	34/40	85.0	32/32	100	91.7	0.97 (0.93-1.00)
Strongyloides	NIE	37/40	92.5	29/32	90.6	91.7	37/40	92.5	32/32	100	95.8	0.96 (0.91-1.00)
Schistosoma spp	Sm - serpin	36/40	90.0	31/32	96.9	93.1	31/40	77.5	32/32	100	87.5	0.95 (0.90-1.00)
	Sh - serpin	36/40	90.0	31/32	96.9	93.1	29/40	72.5	31/32	96.9	83.3	0.92 (0.87-0.99)
	Both	39/40	97.5	30/32	93.8	95.8	36/40	90.0	31/32	96.9	93.1	0.97 (0.93-1.00)

Pos T: positive test; Pos GS: positive Gold Standard; Neg T: Negative test; Neg GS: Negative Gold standard; HIV: Human Immunodeficiency Virus, HBV: Hepatitis B Virus, HCV: Hepatitis C Virus; Sm: *Schistosoma mansoni*; Sh: *Schistosoma haematobium;* NS3: non-structural protein 3; PFR2: paraflagellar rod protein 2; KMP11: kinetoplastid membrane protein-11

Table 3. Performance parameters of the 10 antigens tested in the multiplex assay in a prospective cohort of 48 migrant individuals with risk of exposure to the tested infections.

		2 SD cutoff				3 SD cutoff					AUC	
	U	Pos T / Pos GS		Neg T / Neg GS		Correctly classified		Sensitivity	Neg T / Neg GS		Correctly classified	
HIV	p24	0/1	0	43/45	95.6	93.5	0/1	0	43/45	95.6	93.5	0-48 ( 1.00)
	gp41	1/1	100	39/45	86.7	87.0	0/1	0	44/45	97.8	95.7	0.92 ( 1.00)
HBV	HBV core	11/11	100	33/37	89.2	91.7	7/11	63.6	35/37	94.6	87.5	0.95 (0.90-1.00)
HCV	HCV core	-	-	46/48	95.8	-	-	-	4748	97.9	-	-
	HCV NS3	-	-	45/48	93.8	-	-	-	45/48	93.8	-	-
Chagas disease	PFR2	14/14	100	16/16	100	100	12/14	85.7	16/16	100	93.3	1.00 (1.00-1.00)
	KMP11	14/14	100	16/16	100	100	14/14	100	16/16	100	100	1.00 (1.00-1.00)
	Both	14/14	100	16/16	100	100	14/14	100	16/16	100	100	1.00 (1.00-1.00)
Strongyloides	NIE	5/6	83.3	33/38	86.8	86.4	4/6	66.7	37/38	97.4	93.2	0.88 (0.70-1.00)
Schistosoma	Sm - serpin	-	-	20/22	90.0	-		-	21/22	95.4	-	-
spp	Sh - serpin	_	-	18/22	81.8	-		-	21/22	95.4	-	-
	Both	-	-	18/22	81.8	-		-	21/22	95.4	-	-

Pos T: Positive test; Pos GS: Positive Gold Standard; Neg T: Negative test; Neg GS: Negative Gold standard; HIV: Human Immunodeficiency Virus, HBV: Hepatitis B Virus, HCV: Hepatitis C Virus; Sm: *Schistosoma mansoni*; Sh: *Schistosoma haematobium*; NS3: non-structural protein 3; PFR2: paraflagellar rod protein 2; KMP11: kinetoplastid membrane protein-11

#### **FIGURES**

**Figure 1.** Dot plots showing the distribution of IgG levels measured against the 10 multiplexed antigens in the different panels of samples

1A. Panels of positive and negative control samples for each infection

1B. Panel of test samples from the migrants cohort


Legend:


The positive samples (1A) were selected based on seropositivity in the reference methods. In total, 40 positive samples were included for the respective infections (n=240).

Log10MFI: IgG serological levels (log10 mean fluorescence intensity); HBV: Hepatitis B

Virus, HCV: Hepatitis C Virus: Sm: Schistosoma mansoni; Sh: Schistosoma haematobium

**Figure 2.** Receiver operating curves for the 10 antigens tested in the multiplex assay to detect the infections.





 $\mathbf{\omega}$ 

